首页 | 本学科首页   官方微博 | 高级检索  
     


A chondroitin synthase-1 (ChSy-1) missense mutation in a patient with neuropathy impairs the elongation of chondroitin sulfate chains initiated by chondroitin N-acetylgalactosaminyltransferase-1
Authors:Tomomi Izumikawa  Kazumasa Saigoh  Jun Shimizu  Shoji Tsuji  Susumu Kusunoki  Hiroshi Kitagawa
Affiliation:1. Department of Biochemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe 658-8558, Japan;2. Department of Neurology, Kinki University School of Medicine, Osaka-Sayama, Osaka 589-8511, Japan;3. Department of Neurology, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan
Abstract:

Background

Previously, we identified two missense mutations in the chondroitin N-acetylgalactosaminyltransferase-1 gene in patients with neuropathy. These mutations are associated with a profound decrease in chondroitin N-acetylgalactosaminyltransferase-1 enzyme activity. Here, we describe a patient with neuropathy who is heterozygous for a chondroitin synthase-1 mutation. Chondroitin synthase-1 has two glycosyltransferase activities: it acts as a GlcUA and a GalNAc transferase and is responsible for adding repeated disaccharide units to growing chondroitin sulfate chains.

Methods

Recombinant wild-type chondroitin synthase-1 enzyme and the F362S mutant were expressed. These enzymes and cells expressing them were then characterized.

Results

The mutant chondroitin synthase-1 protein retained approximately 50% of each glycosyltransferase activity relative to the wild-type chondroitin synthase-1 protein. Furthermore, unlike chondroitin polymerase comprised of wild-type chondroitin synthase-1 protein, the non-reducing terminal 4-O-sulfation of GalNAc residues synthesized by chondroitin N-acetylgalactosaminyltransferase-1 did not facilitate the elongation of chondroitin sulfate chains when chondroitin polymerase that consists of the mutant chondroitin synthase-1 protein was used as the enzyme source.

Conclusions

The chondroitin synthase-1 F362S mutation in a patient with neuropathy resulted in a decrease in chondroitin polymerization activity and the mutant protein was defective in regulating the number of chondroitin sulfate chains via chondroitin N-acetylgalactosaminyltransferase-1. Thus, the progression of peripheral neuropathies may result from defects in these regulatory systems.

General significance

The elongation of chondroitin sulfate chains may be tightly regulated by the cooperative expression of chondroitin synthase-1 and chondroitin N-acetylgalactosaminyltransferase-1 in peripheral neurons and peripheral neuropathies may result from synthesis of abnormally truncated chondroitin sulfate chains.
Keywords:CS, chondroitin sulfate   ChSy, chondroitin synthase   ChGn, chondroitin GalNAcT   ChPF, chondroitin polymerizing factor   GalNAcT, N-acetylgalactosaminyltransferase   GlcAT, glucuronyltransferase   ΔDi-0S, ΔHexA(α1&ndash  3)GalNAc   ΔDi-6S, ΔHexAα1&ndash  3GalNAc(6S)   ΔDi-4S, ΔHexAα1&ndash  3GalNAc(4S)   ΔDi-diSD, ΔHexA(2S)α1&ndash  3GalNAc(6S)   ΔDi-diSE, ΔHexAα1&ndash  3GalNAc(4S, 6S)
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号